{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:57:14Z","timestamp":1770818234318,"version":"3.50.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.0213","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T16:32:03Z","timestamp":1551457923000},"page":"e190213","source":"Crossref","is-referenced-by-count":16,"title":["Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease"],"prefix":"10.1001","volume":"2","author":[{"given":"Alvaro","family":"San-Juan-Rodriguez","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Melbourne Institute, Faculty of Business and Economics, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"issue":"3","key":"zoi190021r1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi190021r2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","article-title":"2018 Alzheimer\u2019s disease facts and figures.","volume":"14","author":"Alzheimer\u2019s Association","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"4","key":"zoi190021r4","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer\u2019s disease.","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi190021r5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"41","author":"Tan","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"zoi190021r6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-122140","article-title":"A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer\u2019s disease.","volume":"35","author":"Di Santo","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi190021r7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cpt.1104","article-title":"Monotherapy is good enough for patients with mild-to-moderate Alzheimer\u2019s disease: a network meta-analysis of 76 randomized controlled trials.","volume":"105","author":"Tsoi","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi190021r8","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease.","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"zoi190021r9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.","volume":"148","author":"Raina","year":"2008","journal-title":"Ann Intern Med"},{"key":"zoi190021r10","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/DDDT","article-title":"A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease.","volume":"10","author":"Deardorff","year":"2016","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"zoi190021r11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease.","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi190021r12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"zoi190021r13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/gps.v29.9","article-title":"The effects of combine treatment of memantine and donepezil on Alzheimer\u2019s disease patients and its relationship with cerebral blood flow in the prefrontal area.","volume":"29","author":"Araki","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"zoi190021r14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors.","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"issue":"8","key":"zoi190021r15","doi-asserted-by":"publisher","first-page":"e0183586","DOI":"10.1371\/journal.pone.0183586","article-title":"Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis.","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"zoi190021r16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/ene.12707","article-title":"EFNS-ENS\/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer\u2019s disease.","volume":"22","author":"Schmidt","year":"2015","journal-title":"Eur J Neurol"},{"issue":"6","key":"zoi190021r17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40264-014-0161-z","article-title":"Cardiovascular effects of drugs used to treat Alzheimer\u2019s disease.","volume":"37","author":"Howes","year":"2014","journal-title":"Drug Saf"},{"issue":"22","key":"zoi190021r18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment.","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"issue":"11","key":"zoi190021r19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/jgs.2009.57.issue-11","article-title":"Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England healthcare system.","volume":"57","author":"Hernandez","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"zoi190021r20","doi-asserted-by":"publisher","first-page":"e1000157","DOI":"10.1371\/journal.pmed.1000157","article-title":"Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.","volume":"6","author":"Park-Wyllie","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"zoi190021r21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"issue":"6","key":"zoi190021r22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/jgs.2011.59.issue-6","article-title":"Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.","volume":"59","author":"Kim","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"zoi190021r23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jjcc.2009.03.011","article-title":"Torsades de pointes with QT prolongation related to donepezil use.","volume":"54","author":"Takaya","year":"2009","journal-title":"J Cardiol"},{"issue":"2","key":"zoi190021r24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1345\/aph.1K514","article-title":"Prolonged QT interval, syncope, and delirium with galantamine.","volume":"42","author":"Fisher","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"6","key":"zoi190021r25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","article-title":"Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).","volume":"18","author":"Poluzzi","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7619","key":"zoi190021r26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.39020.710602.47","article-title":"Calculate the QT interval in patients taking drugs for dementia.","volume":"335","author":"Leitch","year":"2007","journal-title":"BMJ"},{"issue":"12","key":"zoi190021r27","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/jgs.2012.60.issue-12","article-title":"Comparative cardiovascular safety of dementia medications: a cross-national study.","volume":"60","author":"Fosb\u00f8l","year":"2012","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"zoi190021r28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/pds.v17:9","article-title":"Does memantine induce bradycardia? a study in the French PharmacoVigilance Database.","volume":"17","author":"Gallini","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi190021r30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40120-017-0067-7","article-title":"A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer\u2019s disease patients.","volume":"6","author":"Bent-Ennakhil","year":"2017","journal-title":"Neurol Ther"},{"issue":"9596","key":"zoi190021r31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"zoi190021r32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","article-title":"Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.","volume":"80","author":"Lopez","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"zoi190021r33","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S1474-4422(15)00258-6","article-title":"Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer\u2019s Disease (DOMINO-AD) trial: secondary and post-hoc analyses.","volume":"14","author":"Howard","year":"2015","journal-title":"Lancet Neurol"},{"issue":"5","key":"zoi190021r34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/08959420.2017.1281092","article-title":"A focus on the Program of All-Inclusive Care for the Elderly (PACE).","volume":"29","author":"Gonzalez","year":"2017","journal-title":"J Aging Soc Policy"},{"key":"zoi190021r3","unstructured":"Administration on Aging, Administration for Community Living, US Department of Health and Human Services. A profile of older Americans: 2016. https:\/\/acl.gov\/sites\/default\/files\/Aging%20and%20Disability%20in%20America\/2016-Profile.pdf. Accessed April 12, 2018."},{"key":"zoi190021r29","unstructured":"Center for Medicare and Medicaid Services Chronic Conditions Data Warehouse. Condition categories. https:\/\/www.ccwdata.org\/web\/guest\/condition-categories. Accessed April 26, 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/3\/e190213\/17317998\/sanjuanrodriguez_2019_oi_190021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T16:32:18Z","timestamp":1551457938000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.0213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0213","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}